Refine
Year of publication
Document Type
- Article (33)
Language
- English (33) (remove)
Has Fulltext
- yes (33)
Is part of the Bibliography
- no (33)
Keywords
- apoptosis (2)
- curcumin (2)
- 2‑methoxyestradiol (1)
- Bee venom allergy (1)
- C6 ceramide (1)
- Colorectal cancer (1)
- Hymenoptera venom allergy (1)
- Hymenoptera venom immunotherapy (1)
- Immunotherapy (1)
- Inflammation (1)
- Interleukin (1)
- Interleukin-6 (1)
- JAWSTAT pathway (1)
- Keratinocytes (1)
- Ki-67 (1)
- LC3 I/II (1)
- NFκB (1)
- PPAR (1)
- Promoters (1)
- Quality of life (1)
- Reactive oxygen species (1)
- Rush protocol (1)
- S100 calcium‑binding protein B (1)
- STAT3 (1)
- Spa water (1)
- Sting challenge (1)
- Thermal spring water (1)
- Tumor interstitial fluid pressure (1)
- UVA (1)
- Ultra-rush protocol (1)
- VIS (1)
- Vespid venom allergy (1)
- adipocytes (1)
- adiponectin (1)
- adipose-derived stem cells (1)
- ageing (1)
- anti-bacterial agents (1)
- anti-inflammatory agent (1)
- autophagy (1)
- caspase-8 (1)
- cell cycle arrest (1)
- cell proliferation (1)
- collagen I (1)
- colorectal carcinoma (1)
- cross reactivity (1)
- cutaneous T cell lymphoma (1)
- cyclin D1 (1)
- death receptor (1)
- differentiation (1)
- dimethylfumarate (1)
- discoidin domain-containing receptor (1)
- head and neck cancer (1)
- hidradenitis suppurativa (1)
- imiquimod (1)
- integrins (1)
- lactate dehydrogenase (1)
- locusts (1)
- mRNA (1)
- mTORC (1)
- mantle cell lymphoma (1)
- mechanical stimuli (1)
- melanoma (1)
- non‑Hodgkin's lymphoma (1)
- occupational immediate-type reactions (1)
- p21 (1)
- p44/42 MAPK (1)
- p62 (1)
- peripheral blood stem cell transplant (1)
- prognostic factor (1)
- proliferation (1)
- psoriasis (1)
- rapamycin (1)
- retuximab (1)
- rifampin (1)
- sex‑determining region Y-box 11 (1)
- short-chain ceramide (1)
- skin (1)
- skin involvement (1)
- stage (1)
- subcutaneous fat (1)
- therapeutics (1)
- tumor cell proliferation (1)
- xenograft (1)
Institute
- Medizin (32)
- Biowissenschaften (2)
- Georg-Speyer-Haus (1)
Background: SARS-CoV-2 has massively changed the care situation in hospitals worldwide. Although tumour care should not be affected, initial reports from European countries were suggestive for a decrease in skin cancer during the first pandemic wave and only limited data are available thereafter.
Objectives: The aim of this study was to investigate skin cancer cases and surgeries in a nationwide inpatient dataset in Germany.
Methods: Comparative analyses were performed in a prepandemic (18 March 2019 until 17 March 2020) and a pandemic cohort (18 March 2020 until 17 March 2021). Cases were identified and analysed using the WHO international classification of diseases codes (ICDs) and process key codes (OPSs).
Results: Comparing the first year of the pandemic with the same period 1 year before, a persistent decrease of 14% in skin cancer cases (n = 19 063) was observed. The largest decrease of 24% was seen in non-invasive in situ tumours (n = 1665), followed by non-melanoma skin cancer (NMSC) with a decrease of 16% (n = 15 310) and malignant melanoma (MM) with a reduction of 7% (n = 2088). Subgroup analysis showed significant differences in the distribution of sex, age, hospital carrier type and hospital volume. There was a decrease of 17% in surgical procedures (n = 22 548), which was more pronounced in minor surgical procedures with a decrease of 24.6% compared to extended skin surgery including micrographic surgery with a decrease of 15.9%.
Conclusions: Hospital admissions and surgical procedures decreased persistently since the beginning of the pandemic in Germany for skin cancer patients. The higher decrease in NMSC cases compared to MM might reflect a prioritization effect. Further evidence from tumour registries is needed to investigate the consequences of the therapy delay and identify the upcoming challenges in skin cancer care.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of the hair follicles leading to painful lesions, associated with increased levels of pro-inflammatory cytokines. Numerous guidelines recommend antibiotics like clindamycin and rifampicin in combination, as first-line systemic therapy in moderate-to-severe forms of inflammation. HS has been proposed to be mainly an auto-inflammatory disease associated with but not initially provoked by bacteria. Therefore, it has to be assumed that the pro-inflammatory milieu previously observed in HS skin is not solely dampened by the bacteriostatic inhibition of DNA-dependent RNA polymerase. To further clarify the mechanism of anti-inflammatory effects of rifampicin, ex vivo explants of lesional HS from 8 HS patients were treated with rifampicin, and its effect on cytokine production, immune cells as well as the expression of Toll-like receptor 2 (TLR2) were investigated. Analysis of cell culture medium of rifampicin-treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1β, IL-6, IL-8, IL-10 and tumour necrosis factor (TNF)-α production. Immunohistochemistry of the rifampicin-treated explants suggested a tendency for it to reduce the expression of TLR2 while not affecting the number of immune cells.